

Gilead  
Liver Franchise Brochure  
IHQ-UNB-1932  
8.25 in. wide x 11.75 in. high



Front Cover

11.75"



Inside Spread



Back Cover

8.25"

# *Advancing* LIVER HEALTH

Envisioning a better future for patients

Gilead has a long history of commitment to **TRANSFORMING** the lives of those living with liver disease.

Our **INNOVATION** forms the foundation upon which new medicines are developed and brought to those who need them most.

And our **COLLABORATIVE** culture joins our efforts with those of industry partners and the liver community to ensure that every patient has access to *transformative treatments*.



GILEAD

| LIVER

Gilead creates **TRANSFORMATIVE  
MEDICINES** that can change lives.



*Today, our medicines are prescribed by  
healthcare professionals for millions  
of people all over the world.<sup>1-5</sup>*

OVER  
**20**  
YEARS

For more than 20 years, Gilead's success at finding innovative liver disease medicines has been helping transform the lives of those living with liver diseases across the globe.<sup>4,5</sup>

## TRANSFORMATIVE MEDICINES



Worldwide, **1.5 BILLION PEOPLE** are **AFFECTED BY LIVER DISEASES**, resulting in an estimated 2 million deaths per annum.<sup>6,7</sup> At Gilead, we've introduced multiple medicines for the treatment and elimination of viral hepatitis and have successfully brought to market multiple liver medications, each offering a transformative viral hepatitis treatment.<sup>8-13</sup>



Our medicines have helped to treat and manage hepatitis B virus (HBV).<sup>12</sup> These medicines have been registered to **TREAT HBV** in more than 60 low- and middle-income countries.<sup>14</sup>



We've transformed hepatitis C virus (HCV) management with oral direct-acting antiviral agents (DAAs) that **ACHIEVE HIGH CURE RATES**, potentially making elimination possible.<sup>2,9,13,15-17</sup>



We are striving to **IMPROVE OUTCOMES** for people with chronic hepatitis delta (HDV).<sup>11</sup>



Through dedicated research and development, complemented by our invaluable external partnerships, Gilead has helped **TRANSFORM TREATMENT** for people living with viral hepatitis.<sup>1,18</sup>

Gilead is contributing to the **FUTURE**  
of liver disease treatments.<sup>19</sup>



*Gilead's commitment to finding liver disease treatments and cures is the force that continues to drive us forward in pursuit of changing the lives of those living with liver disease.*



Through **innovative partnerships** and collaborations, our goal is to advance the quality of existing liver treatments while uncovering new indications for which there are no approved therapies.

## INNOVATIVE PIPELINE



At Gilead, we're pioneering a comprehensive liver pipeline in a relentless pursuit to deliver innovative, transformative treatments for those living with liver disease. We continue to leverage translational medicine and data-driven approaches to **IDENTIFY THE RIGHT TREATMENTS** for these individuals.<sup>19</sup>



Leveraging experience in HCV cure, we are focused on partnerships to **ADVANCE HBV AND HDV CURE RESEARCH PROGRAMS**.<sup>2</sup>



We're **COLLABORATING WITH INDUSTRY LEADERS** and top research institutions on nonalcoholic steatohepatitis (NASH) research. Working with industry partners, we've improved diagnosis of NASH via a noninvasive technology.<sup>20-21</sup>



We're **SPEARHEADING RESEARCH** into investigational treatments of primary sclerosing cholangitis (PSC).<sup>22</sup>

At Gilead, we form our  
**COLLABORATIONS** around a common goal.



*At Gilead, we're dedicated to creating  
partnerships that increase access to  
transformative medicines for individuals living  
with liver diseases around the globe.*



We're continuously **pursuing, identifying, and  
addressing the unmet needs** of people all over  
the world who are living with liver diseases.

## COLLABORATIVE WORK



For more than 20 years, Gilead has made its liver medicines available through access programs.<sup>5</sup> Everything we do is in service of our ultimate objective: to continue to work toward the World Health Organization (WHO) goal of **ELIMINATING VIRAL HEPATITIS AS A PUBLIC HEALTH THREAT** by the year 2030. Having treated over 1 million individuals in the US alone,<sup>23</sup> Gilead's HCV portfolio helps to support these efforts.



In 2021, Gilead and Vir Biotechnology established a **CLINICAL COLLABORATION** to explore combination strategies for a functional cure for chronic HBV.<sup>24</sup>



The Gilead Foundation, a nonprofit organization established in 2005, seeks to improve the health and well-being of underserved communities around the world by **PROVIDING PROGRAM FUNDING**.<sup>25</sup>



We're working toward the WHO goal by **ACTIVELY SUPPORTING THE EFFORTS** of governments, patient organizations, payers, and healthcare providers to increase awareness, drive screening, and facilitate linkage to care.<sup>26</sup>



# Advancing LIVER HEALTH

Envisioning a better future for patients



TRANSFORM



INNOVATE



COLLABORATE



**References:** **1.** Data on File. Viral Diseases Deep Dive. **2.** Sajed N, Hutchison K, Rossaro L, et al. Gilead HCV Poster Release: Support of Global Efforts Towards Elimination of Hepatitis C Virus. 2017. **3.** Marcellin P, Gane E, Buti M, et al., Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*, 2013. 381(9865): p. 468-75. **4.** Data on File. Gilead Our Mission 2017. **5.** Gilead Sciences, Press Release: Gilead Sciences' Hepatitis B Drug Hepsera Approved for Marketing in European Union. **6.** Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. *Clin Gastroenterol Hepatol*. 2020;18(12):2650-2666. doi:10.1016/j.cgh.2019.07.060 **7.** Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol*. 2019;70(1):151-171. doi:10.1016/j.jhep.2018.09.014 **8.** Rabaan AA, Al-Ahmed SH, Bazzi AM, et al. Overview of hepatitis C infection, molecular biology, and new treatment. *J Infect Public Health*, 2020. 13(5): p. 773-783. **9.** Keating, G.M., Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. *Drugs*, 2015. 75(6): p. 675-85. **10.** Keating, G.M., Sofosbuvir: a review of its use in patients with chronic hepatitis C. *Drugs*, 2014. 74(10): p. 1127-46. **11.** Kang, C. and Y.Y. Syed, Bulevirtide: First Approval. *Drugs*, 2020. 80(15): p. 1601-1605. **12.** Scott, L.J. and H.L.Y. Chan, Tenofovir Alafenamide: A Review in Chronic Hepatitis B. *Drugs*, 2017. 77(9): p. 1017-1028. **13.** Heo, Y.A. and E.D. Deeks, Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. *Drugs*, 2018. 78(5): p. 577-587. **14.** Gilead Impact Report. **15.** Administration, U.F.a.D., FDA approves Epclusa for treatment of chronic Hepatitis C virus infection. 2016. **16.** Henry B. DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS. *J Health Biomed Law*. 2018;14:265-283. **17.** Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. *Liver Int*, 2020. 40(8): p. 1841-1852. **18.** Fibrotic Diseases Deep Dive. Data on File. **19.** Gilead Pipeline 2021. [cited 2022 April 2022]; Available from: <https://www.gilead.com/science-and-medicine/pipeline> **20.** Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. *Hepatology*, 2019. 70(5): p. 1521-1530. **21.** Gilead Sciences, Press Release: Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018. **22.** Gilead Sciences, Press Release: Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018. **23.** Data on File. US HCV Totals Sof-Based Regimens. Gilead Sciences. **24.** Gilead Sciences, Press Release: Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus. **25.** Gilead Sciences, Press Release: Gilead Sciences Endows Its Foundation With More Than \$200 Million to Support Health Justice, Community Giving and Employee Match Program. **26.** Gilead Corporate Website April 2022; Available from: <https://www.gilead.com/>.